DNLI
Denali Therapeutics Inc.
There isn't enough reported data to score DNLI yet.
DNLI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
DNLI's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
DNLI PE Valuation
DNLI has no meaningful PE right now: it lost money over the past year.
DNLI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DNLI's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
DNLI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.73 | +$1.18 |
| Q2 2026 | -$2.84 | -$0.04 |
| Q1 2026 | -$2.88 | -$0.21 |
| Q4 2025 | -$2.97 | -$0.40 |
| Q3 2025 | -$2.91 | -$0.17 |
| Q2 2025 | -$2.80 | +$0.03 |
| Q1 2025 | -$2.67 | -$1.73 |
| Q4 2024 | -$2.57 | -$1.51 |
DNLI lost $1.73 per share over the past year, a smaller loss than the year before.
DNLI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $1.3M | -64% |
| Q2 2023 | $294.1M | +460% |
| Q1 2023 | $35.1M | -17% |
| Q4 2022 | $10.3M | -18% |
| Q3 2022 | $3.6M | -33% |
| Q2 2022 | $52.5M | +129% |
| Q1 2022 | $42.1M | +432% |
| Q4 2021 | $12.5M | -96% |
DNLI's revenue is growing: $18M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -713% | N/A |
| Q2 2026 | -3622% | N/A |
| Q3 2023 | -8981% | -5961 points |
| Q2 2023 | 58% | +175 points |
| Q1 2023 | -344% | -186 points |
| Q4 2022 | -1024% | -408 points |
| Q3 2022 | -3020% | -1401 points |
| Q2 2022 | -117% | +153 points |
DNLI's operating margin was −713% last quarter, down 369 points from the same quarter a year ago.
DNLI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$118.5M | -$12.5M |
| Q2 2026 | -$97.8M | -$18.2M |
| Q1 2026 | -$133.7M | +$2.9M |
| Q4 2025 | -$100.1M | -$11.3M |
| Q3 2025 | -$105.9M | -$42.9M |
| Q2 2025 | -$79.6M | +$16.4M |
| Q1 2025 | -$136.5M | -$20.8M |
| Q4 2024 | -$88.8M | +$12.1M |
DNLI has burned cash in almost every quarter: −$450M over the past year, against −$411M the year before.
DNLI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +4.8M shares |
| 1 year | +11% | +19.7M shares |
| 3 years | +40% | +54.4M shares |
| 5 years | +58% | +70.3M shares |
| Available history | +100% | +96M shares |
DNLI has 192M diluted shares, up 11% from a year ago.
DNLI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -11.6x | Net Cash |
| Q2 2021 | -8.2x | Net Cash |
| Q1 2021 | -7.3x | Net Cash |
| Q4 2020 | -7.1x | Net Cash |
DNLI has more cash than debt.
DNLI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.5 | Neutral |
| Stochastic | 23.4 | Neutral |
DNLI's weekly RSI is 44 (neutral) and its Stochastic is 23 (neutral).
DNLI PE vs Healthcare Sector
| Metric | DNLI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DNLI has no meaningful PE right now: it lost money over the past year.
DNLI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 1.7% below |
| 20 week MA | $21.8 | 13% below |
| 50 week MA | $20.6 | 8.1% below |
| 100 week MA | $18.4 | 2.9% above |
| 200 week MA | $21.0 | 9.8% below |
DNLI's trend is mixed: it's above one of its five weekly moving averages, and 9.8% below its 200-week average.
DNLI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.3 | $85.9 | +370% |
| 2021 | $85.9 | $47.5 | -45% |
| 2022 | $47.5 | $27.9 | -41% |
| 2023 | $27.9 | $21.5 | -23% |
| 2024 | $21.5 | $20.6 | -4% |
| 2025 | $20.6 | $16.9 | -18% |
| 2026 YTD | $16.9 | $18.9 | +12% |
DNLI has finished five years in a row lower, and it's up 12% so far in 2026.